Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (120)	9/14/2006 9:46:25 AM
From: Ian@SI	Read Replies (1) \| Respond to of 507

Well it went up $0.21 for at least one trade this morning. <G> I'm beginning to suspect that the market is uneasy about the lawsuit; and that the stock won't go up much prior to its resolution. +++++++++++++++ Pfizer: More Patients Would Use Insulin With Exubera djones COPENHAGEN -(Dow Jones)- U.S. pharmaceutical company Pfizer Inc. (PFE) on Thursday published new research data on its inhaled insulin Exubera, which showed the new diabetes treatment would encourage more patients with type two diabetes to accept insulin treatment, even in countries that already have easy- to-use insulin pens. According to the new data, which was presented at the European Association for the Study of Diabetes, or EASD conference in Copenhagen on Thursday, 44% of patients with uncontrolled type two diabetes would be encouraged to accept insulin therapy with Exubera as an option, compared to only 17% when Exubera wasn't presented as an option. Exubera this summer became the first inhaled insulin to enter the European and U.S. markets. It was launched in Germany in May and in the U.S. in September and Pfizer has said it expects the drug to become a blockbuster, exceeding $1 billion in annual sales. However, the future of Exubera is dependent on a lawsuit regarding the patent of the treatment, filed by Novo Nordisk A/S (NVO) in August. The competing Danish pharmaceutical company claims Exubera infringes its patents covering methods of administering inhaled insulin to diabetics, and a hearing is expected in New York early December. Further studies about Exubera which were presented at the conference showed that less weight gain was observed in patients using Exubera compared to patients using injected insulin and that the treatment could, contrary to what some had feared, be used when patients suffered from chest infections and in smoky environments. According to the data, patients with type one diabetes gained a mean of 0.2 kilograms on Exubera compared with 1.1 kilograms on injected insulin over six months. Patients with type two diabetes gained 0.7 kilograms using Exubera compared with 1.6 kilograms using injected insulin. Contrary to the effect of active smoking, the data showed that passive smoking reduces the rate and extent of inhaled insulin absorption, hence it doesn't present an increased risk of hypoglycemia, Pfizer said. However, patients who smoke, suffer from asthma or get severe lung infections such as pneumonia shouldn't use Exubera. Pfizer developed Exubera together with Nektar Therapeutics (NKTR) and the treatment was approved by the U.S. Food and Drug Administration in January 2006. According to the International Diabetes Federation, more than 230 million people suffer from diabetes worldwide and the number is expected to grow to 350 million by 2025. [snip]